P&G Likely To Keep Prilosec OTC, Vicks In Portfolio Shuffle – Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
P&G’s plan to sell half of its brands triggered speculation about what the firm will keep and what it will sell. A Bernstein analyst predicts the firm will part with many oral care products and dietary supplements, but will keep consumer health brands including Prilosec OTC, Vicks and Crest.
You may also be interested in...
Unilever Grows European Portfolio, P&G Trims More Brands In Toothpaste Deal
Fluocaril and Parogencyl are “well-known” toothpastes that have garnered “strong endorsement from health professionals,” Unilever says. The brands, identified by analysts as potential candidates for sale, are latest in P&G’s ongoing trimming of lower-selling lines.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.